|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical significance of type V_I pit pattern subclassification in determining the depth of invasion of colorectal neoplasms显示文摘AIM: To clarify whether subclassification of the type VI pit pattern on the basis of magnifying colonoscopy findings is useful in determining the type and depth of invasion of colorectal neoplasms.METHODS: We retrospectively analyzed 272 colorectal neoplasms (117 dysplasias and 155 submucosal invasive carcinomas; 228 patients) with a type V pit pattern [type VI, n = 202; type VN, n = 70 (Kudo and Tsuruta classification system)]. We divided lesions with a type VI pit pattern into two subclasses, mildly irregular lesions and severely irregular lesions, according to the prominent and detailed magnifying colonoscopy findings. We examined the relation between these two subclasses and histology/invasion depth.RESULTS: One hundred and four lesions (51.5%) were judged to be mildly irregular, and 98 lesions (48.5%) were judged to be severely irregular. Ninety-seven (93.3%) mildly irregular lesions showed dysplasias or submucosal invasion of less than 1000 μm (SM < 1000 μm). Fifty-five (56.1%) severely irregular lesions showed submucosal invasion equal to or deeper than 1000 μm (SM ≥ 1000 μm). Mild irregularity was found significantly more often in dysplasias or lesions with SM < 1000 μm than in lesions with SM ≥ 1000 μm (P < 0.01).CONCLUSION: Subclassification of the type VI pit pattern is useful for identifying dysplasias or lesions with SM < 1000 μm. | Hiroyuki Kanao Shinji Tanaka Shiro Oka Iwao Kaneko Shigeto Yoshida Koji Arihiro Masaharu Yoshihara Kazuaki Chayama | 2008 | World Journal of Gastroenterology2008，14，2： | 15 |
| 2 | Immunohistochemical molecular markers as predictors of curability of endoscopically resected submucosal colorectal cancer显示文摘AIM: To clarify the usefulness of immunohistochemical molecular markers in predicting lymph node metastasis of submucosal colorectal cancer. METHODS: We examined microvessel density, lymphatic vessel density, the Ki-67 labeling index, expression of MUC1 and Matrix metalloproteinase-7 (MMP-7) in tumor cells, and expression of cathepsin D in stromal cells at the invasive front by immunostaining of samples resected from 214 patients with submucosal colorectal cancer. Pathologic features were assessed on hematoxylin-eosin- stained samples. We evaluated the relations between clinicopathologic/immunohistochemical features and lymph node metastasis. RESULTS: Lesions of the superficial type, with an unfavorable histologic grade, budding, lymphatic involvement, high microvessel density (≥ 40), high lymphatic vessel density (≥ 9), high Ki-67 labeling index (≥ 42), and positivity of MUC1, cathepsin D, and MMP-7 showed a significantly high incidence of lymph node metastasis. Multivariate analysis revealed that high microvessel density, unfavorable histologic grade, cathepsin D positivity, high lymphatic vessel density, superficial type, budding, and MUC1 positivity were independent risk factors for lymph node metastasis.A combined examination with four independent immunohistochemical markers (microvessel density, cathepsin D, lymphatic vessel density, and MUC1) revealed that all lesions that were negative for all markers or positive for only one marker were negative for lymph node metastasis. CONCLUSION: Analysis of a combination of immuno- histochemical molecular markers in endoscopically resected specimens of submucosal colorectal cancer allows prediction of curability regardless of the pathologic features visible of hematoxylin-eosin-stained sections. | Iwao Kaneko Shinji Tanaka Shiro Oka Shigeto Yoshida Toru Hiyama Koji Arihiro Fumio Shimamoto Kazuaki Chayama | 2007 | World Journal of Gastroenterology2007，13，28： | 12 |
| 3 | Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer显示文摘 | Shiro Oka Shinji Tanaka Iwao Kaneko Ritsuo Mouri Mayuko Hirata Toru Kawamura Masaharu Yoshihara Kazuaki Chayama | 2006 | Gastrointestinal Endoscopy2006，，6： | 6 |
| 4 | Endoscopic submucosal dissection for colorectal neoplasia: possibility of standardization显示文摘 | Shinji Tanaka Shiro Oka Iwao Kaneko Mayuko Hirata Ritsuo Mouri Hiroyuki Kanao Shigeto Yoshida Kazuaki Chayama | 2007 | Gastrointestinal Endoscopy2007，，1： | 5 |
| 5 | Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer显示文摘 | Shiro Oka Shinji Tanaka Iwao Kaneko Ritsuo Mouri Mayuko Hirata Toru Kawamura Masaharu Yoshihara Kazuaki Chayama | 2006 | Gastrointestinal Endoscopy2006，，6： | 2 |
| 6 | Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer显示文摘 | Shiro Oka Shinji Tanaka Iwao Kaneko Ritsuo Mouri Mayuko Hirata Toru Kawamura Masaharu Yoshihara Kazuaki Chayama | 2006 | Gastrointestinal Endoscopy2006，，6： | 1 |
| 7 | Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer显示文摘 | Shiro Oka Shinji Tanaka Iwao Kaneko Ritsuo Mouri Mayuko Hirata Toru Kawamura Masaharu Yoshihara Kazuaki Chayama | 2006 | Gastrointestinal Endoscopy2006，，6： | 1 |
| 8 | Magnifying endoscopy with narrow band imaging for diagnosis of colorectal tumors显示文摘 | Mayuko Hirata Shinji Tanaka Shiro Oka Iwao Kaneko Shigeto Yoshida Masaharu Yoshihara Kazuaki Chayama | 2007 | Gastrointestinal Endoscopy2007，，7： | 1 |
| 9 | Effect of Three Types of Mixed Anesthetic 'Agents Ahernate toKetamine in Mice 显示文摘 | Sumiko KAWAI Yasuhiro TAKAGI Shiro KANEKO | 2011 | Tokyo experimental animals2011，60，5： | 1 |
| 10 | Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer 显示文摘 | Shiro Oka Shinji Tanaka Iwao Kaneko | 2006 | Gastrointestinal Endoscopy2006，64，6： | 1 |
| 11 | Phase Ⅰ trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer显示文摘AIM: To evaluate the dose-limiting toxicities(DLTs)and determine the maximum-tolerated dose(MTD) and recommended dose(RD) of combination chemotherapy with gemcitabine, cisplatin and S-1 which is an oral fluoropyrimidine pro-drug in patients with advanced biliary tract cancer.METHODS: Patients with histologically or cytologically confirmed unresectable or recurrent biliary tract cancer were enrolled. The planned dose levels of gemcitabine(mg/m2), cisplatin(mg/m2), and S-1(mg/m2 per day) were as follows: level-1, 800/20/60;level 0, 800/25/60; level 1, 1000/25/60; and level 2,1000/25/80. In each cycle, gemcitabine and cisplatin were administered intravenously on days 1 and 15,and S-1 was administered orally twice daily on days 1to 7 and days 15 to 21, every 4 wk.RESULTS: Twelve patients were enrolled, and level0 was chosen as the starting dose. None of the first three patients had DLTs at level 0, and the dose was escalated to level 1. One of six patients had DLTs(grade 4 febrile neutropenia, leucopenia, and neutropenia; grade 3 thrombocytopenia) at level 1.We then proceeded to level 2. None of three patients had DLTs during the first cycle. Although the MTD was not determined, level 2 was designated at the RD for a subsequent phase Ⅱ study.CONCLUSION: The RD was defined as gemcitabine1000 mg/m2(days 1, 15), cisplatin 25 mg/m2(days1, 15), and S-1 80 mg/m2 per day(days 1-7, 15-21),every 4 weeks. A phase Ⅱ study is planned to evaluate the effectiveness of combination chemotherapy withgemcitabine, cisplatin, and S-1 in advanced biliary tract cancer. | Akinori Watanabe Mitsuhiro Kida Shiro Miyazawa Tomohisa Iwai Kosuke Okuwaki Toru Kaneko Hiroshi Yamauchi Miyoko Takezawa Hiroshi Imaizumi Wasaburo Koizumi | 2015 | World Journal of Gastroenterology2015，21，19： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员